NFE2L2 and non-small cell lung carcinoma: The above results suggest that NRF2 negatively regulates PHKG2 expression, and targeted inhibition of NRF2 can promote ferroptosis after radiotherapy by upregulating PHKG2, thereby reversing NSCLC radioresistance.